menu
Phone: (858) 882-2800
The UltraSEEK Lung Panel enables study of disease progression and resistance in non-small cell lung cancer.
Request A Quote
Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
More
Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study
Vice President, Kingmed Diagnostics
Agena Bioscience Shows Off New Liquid Biopsy QC Assay at AMP, Expects January Launch (GenomeWeb)More
Oncology Solutions BrochureMore
Webinar: A Comparison of Two Liquid Biopsy Approaches in Advanced Lung CarcinomaMore
AMP 2019 Video: Liquid Biopsy Interview with Prof. Pierre-Jean LamyMore
Poster: Establishing the Sensitivity, Specificity, Interlaboratory Reproducibility, and Analytical Limit of Detection of the UltraSEEK Liquid Biopsy ApplicationMore
Poster: Application of a Staged Testing Model for cfDNA Samples from NSCLC Patients Progressing on EGFR Tyrosine Kinase Inhibitor TherapyMore